News
Istaroxime has previously completed two positive Phase 2 studies in SCAI ... Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock ...
Istaroxime has previously completed two positive Phase 2 studies in SCAI ... Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock ...
Hosted on MSN8mon
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected MilestonesLead Drug Candidates, New Phase 2b Clinical Trial ... administering istaroxime to patients with the more severe form of cardiac shock, SCAI Stage C. WINT is also developing next generation ...
(MENAFN- GlobeNewsWire - Nasdaq) Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock ... Windtree's portfolio of product candidates includes ...
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic ... a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated ...
today announced it is targeting the planned interim analysis results for the istaroxime cardiogenic shock SEISMiC SCAI Stage C Phase 2 study (the “SEISMiC C Study”) for July 2025. The SEISMiC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback